Abstract
One bioequivalence study was carried out in healthy volunteers in order to compare the rate and extent of absorption of two oral formulations of quetiapine fumarate (CAS 111974-72-2) 25mg film-coated tablet. Thirty subjects were administered quetiapine fumarate film-coated tablet of test and reference formulation in an open-label, randomised, fasting, two-period, two-sequence, crossover study. Blood samples were taken before and within 48 h after drug administration. Plasma concentrations were determined by LC/ MS/MS. Log-transformed AUC and Cmax values were tested for bioequivalence based on the ratios of the geometric means (test/reference). Tmax was analysed nonparametrically. The 90% confidence intervals of the geometric mean values for the test/reference ratios for AUC0-t and Cmax were within the bioequivalence acceptance range of 80-125%. It may be therefore concluded that the test formulation of quetiapine fumarate 25mg filmcoated tablet is bioequivalent to the reference product and can be prescribed interchangeably. © ECV • Editio Cantor Verlag.
| Original language | English |
|---|---|
| Pages (from-to) | 489-493 |
| Journal | Arzneimittel-Forschung/Drug Research |
| Volume | 61 |
| Issue number | 9 |
| Publication status | Published - 6 Oct 2011 |
Keywords
- Atypical antipsychotic
- Bioequivalence
- Healthy volunteers
- Pharmacokinetics
- Quetiapine fumarate, tablet
Fingerprint Dive into the research topics of 'Bioequivalence evaluation of two oral formulations of quetiapine fumarate in healthy volunteers'. Together they form a unique fingerprint.
Cite this
Cánovas, M., Torres, F., Domenech, G., Cebrecos, J., Pelagio, P., Martińez, G., Polonio, F., & Cabre, F. (2011). Bioequivalence evaluation of two oral formulations of quetiapine fumarate in healthy volunteers. Arzneimittel-Forschung/Drug Research, 61(9), 489-493.